Chronic hand eczema - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Chronic hand eczema - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic hand eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chronic hand eczema: Overview
Chronic hand eczema (CHE) is a common inflammatory skin condition. In Chronic hand eczema, affected areas of skin feel hot, painful, rough, scaly and itchy. There may be itchy little blisters or painful cracks. This may in turn, result in pain when moving the hand and fingers. CHE is a common dermatological condition with frequent relapses, occurs possibly as a result of long-term exposure to various irritants and allergens. There is a large unmet need for effective therapeutics for long-term control of CHE, particularly moderate-to-severe cases. Management of hand eczema is complex because of the broad range of different pathogeneses, courses, and prognoses. Patient education, preventive measures, and the use of emollients are the mainstays in the management of hand eczema. High-potency topical corticosteroids are the treatment of choice, with calcineurin inhibitors used for maintenance.
'Chronic hand eczema - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic hand eczema pipeline landscape is provided which includes the disease overview and Chronic hand eczema treatment guidelines. The assessment part of the report embraces, in depth Chronic hand eczema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic hand eczema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chronic hand eczema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic hand eczema Emerging Drugs
Further product details are provided in the report
Chronic hand eczema: Therapeutic Assessment
This segment of the report provides insights about the different Chronic hand eczema drugs segregated based on following parameters that define the scope of the report, such as:
Chronic hand eczema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic hand eczema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic hand eczema drugs.
Chronic hand eczema Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chronic hand eczema - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic hand eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic hand eczema: Overview
Chronic hand eczema (CHE) is a common inflammatory skin condition. In Chronic hand eczema, affected areas of skin feel hot, painful, rough, scaly and itchy. There may be itchy little blisters or painful cracks. This may in turn, result in pain when moving the hand and fingers. CHE is a common dermatological condition with frequent relapses, occurs possibly as a result of long-term exposure to various irritants and allergens. There is a large unmet need for effective therapeutics for long-term control of CHE, particularly moderate-to-severe cases. Management of hand eczema is complex because of the broad range of different pathogeneses, courses, and prognoses. Patient education, preventive measures, and the use of emollients are the mainstays in the management of hand eczema. High-potency topical corticosteroids are the treatment of choice, with calcineurin inhibitors used for maintenance.
'Chronic hand eczema - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic hand eczema pipeline landscape is provided which includes the disease overview and Chronic hand eczema treatment guidelines. The assessment part of the report embraces, in depth Chronic hand eczema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic hand eczema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic hand eczema R&D. The therapies under development are focused on novel approaches to treat/improve Chronic hand eczema.
- In February 2021, The Food and Drug Administration (FDA) has granted Fast Track designation to gusacitinib (ASN002) for the treatment of moderate to severe chronic hand eczema.
This segment of the Chronic hand eczema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic hand eczema Emerging Drugs
- Delgocitinib: LEO Pharma
- ASN002: Asana BioSciences
Further product details are provided in the report
Chronic hand eczema: Therapeutic Assessment
This segment of the report provides insights about the different Chronic hand eczema drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic hand eczema
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chronic hand eczema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic hand eczema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic hand eczema drugs.
Chronic hand eczema Report Insights
- Chronic hand eczema Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic hand eczema drugs?
- How many Chronic hand eczema drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic hand eczema?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic hand eczema therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic hand eczema and their status?
- What are the key designations that have been granted to the emerging drugs?
- LEO Pharma
- Arcutis Biotherapeutics
- Asana BioSciences
- Delgocitinib
- ARQ 252
- ASN002
Introduction
Executive Summary
Chronic hand eczema: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic hand eczema – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chronic hand eczema companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chronic hand eczema Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Delgocitinib: LEO Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Chronic hand eczema Key Companies
Chronic hand eczema Key Products
Chronic hand eczema- Unmet Needs
Chronic hand eczema- Market Drivers and Barriers
Chronic hand eczema- Future Perspectives and Conclusion
Chronic hand eczema Analyst Views
Chronic hand eczema Key Companies
Appendix
Executive Summary
Chronic hand eczema: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chronic hand eczema – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Chronic hand eczema companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Chronic hand eczema Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Delgocitinib: LEO Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I/II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Chronic hand eczema Key Companies
Chronic hand eczema Key Products
Chronic hand eczema- Unmet Needs
Chronic hand eczema- Market Drivers and Barriers
Chronic hand eczema- Future Perspectives and Conclusion
Chronic hand eczema Analyst Views
Chronic hand eczema Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chronic hand eczema
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chronic hand eczema
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chronic hand eczema
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chronic hand eczema
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
